Citation Impact
Citing Papers
Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice
2002
Baculovirus-mediated expression and purification of human serum paraoxonase 1A
2001
The Gln–Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan
1998
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH
2004
Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice
1998
LDL- is a lipid hydroperoxide-enriched circulating lipoprotein
1997
PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity
2004
Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux
2005
Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL
2004
A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids
2001
Structural and functional diversity of paraoxonases
1996
Effect of Gemfibrozil on HDL-Associated Serum Paraoxonase Activity and Lipoprotein Profile in Patients with Hyperlipidaemia
2000
Native and Modified Low Density Lipoproteins Increase the Functional Expression of the Macrophage Class B Scavenger Receptor, CD36
1997
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
1998 StandoutNature
DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart Disease
1998
Atheroprotective mechanisms of HDL
1999
Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation
2000
Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid
2004
Apo A-I inhibits foam cell formation in apo E–deficient mice after monocyte adherence to endothelium
1999
Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia
2004
Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pH
1998
Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein
1997
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men
1999
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
2007 Standout
Multiple Substrates for Paraoxonase-1 during Oxidation of Phosphatidylcholine by Peroxynitrite
2002
HDL: a recipe for longevity
2004
Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3
2003
Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells
2004
Estrogen receptor α is a major mediator of 17β-estradiol’s atheroprotective effects on lesion size in Apoe–/– mice
2001 StandoutNobel
Macrophages in the Pathogenesis of Atherosclerosis
2011 Standout
Extracellular phospholipases in atherosclerosis
2010
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
High density associated enzymes: their role in vascular biology
1998
Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma
2009
HDL composition and HDL antioxidant capacity in patients on regular haemodialysis
1999
Paraoxonase Genes and Disease
1999
Protective Effect of Paraoxonase Activity in High-Density Lipoproteins against Erythrocyte Membranes Peroxidation: A Comparison between Healthy Subjects and Type 1 Diabetic Patients
2004
Paraoxonase and coronary heart disease
1998
Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL.
1997
Cholesterol, inflammation and innate immunity
2015
Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis
2000 Standout
Plasma platelet activating factor-acetylhydrolase (PAF-AH)
2003
Detailed Molecular Model of Apolipoprotein A-I on the Surface of High-Density Lipoproteins and Its Functional Implications
2000
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.
1996
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein
2001
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
1999 Standout
The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel
2002 StandoutNatureNobel
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
1998 Standout
Antioxidants and Atherosclerotic Heart Disease
1997 Standout
Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
1997
Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.
1995
Presence of paraoxonase in human interstitial fluid
1997
Role of Oxidative Modifications in Atherosclerosis
2004 Standout
On the physiological role(s) of the paraoxonases
1999
PON1 Paraoxonase Activity is Reduced During HDL Oxidation and is an Indicator of HDL Antioxidant Capacity
2002
Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite
2004
The Antiphospholipid Syndrome
2002 Standout
Diabetes and Atherosclerosis
2002 Standout
Glycation impairs high-density lipoprotein function
2000
Oxidized Phosphatidylcholines That Modify Proteins
1996
Mammalian platelet-activating factor acetylhydrolases
1996
Hydrolysis of platelet-activating factor by human serum paraoxonase
2001
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
1998
Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
1998
Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydyl groups
2005
Oxidized phospholipids and isoprostanes in atherosclerosis
1998
Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
1998
Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase
2002
Structural Identification of a Novel Pro-inflammatory Epoxyisoprostane Phospholipid in Mildly Oxidized Low Density Lipoprotein
1999
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
1998 Standout
Protection against Oxidative Stress-induced Cell Death by Intracellular Platelet-activating Factor-Acetylhydrolase II
1997
Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence
1998
Lack of Protection against Oxidative Modification of LDL by Avian HDL
1998
Oxidation of High Density Lipoproteins
1998
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
2004
Atherosclerosis — An Inflammatory Disease
1999 Standout
Inflammation in atherosclerosis
2002 StandoutNature
Inhibition of lipoprotein‐associated phospholipase A2 diminishes the death‐inducing effects of oxidised LDL on human monocyte‐macrophages
2001
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.
1996
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities
2005 Standout
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
1996
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
2003
Paraoxonase Activity Is Reduced by a Pro-atherosclerotic Diet in Rabbits
2000
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
1998
The role of oxidized lipoproteins in atherogenesis
1996
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response
2003
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio.
1997
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Atherosclerosis
2000 StandoutNature
Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo
1997
Acute-Phase Proteins and Other Systemic Responses to Inflammation
1999 Standout
The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns.
1996
Understanding biophysicochemical interactions at the nano–bio interface
2009 Standout
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon
1997
Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis
2000 Standout
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.
1995 Standout
Atherosclerosis
2001 Standout
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.
1998 Standout
Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma.
1996
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.
1997
Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles
2003
Does paraoxonase play a role in susceptibility to cardiovascular disease?
1999
Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
1999
Inhibition of VCAM-1 Expression in Endothelial Cells by Reconstituted High Density Lipoproteins
1997
A review of CETP and its relation to atherosclerosis
2004
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
2006 Standout
Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis
1998
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation
2001
HDL and arteriosclerosis: beyond reverse cholesterol transport
2002
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
Human Serum Paraoxonase/Arylesterase’s Retained HydrophobicN-Terminal Leader Sequence Associates With HDLs by Binding Phospholipids
1999
The codon 55 polymorphism in the paraoxonase 1 gene is not associated with the risk of coronary heart disease in Asian Indians and Chinese
1998
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3
2000
HDL and ApoA Prevent Cell Death of Endothelial Cells Induced by Oxidized LDL
1997
HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis
2008
Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II
2002
Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids
2001
Paraoxonase Genotypes, Lipoprotein Lipase Activity, and HDL
1996
Interleukin-10 Blocks Atherosclerotic Events In Vitro and In Vivo
1999
High-Density Lipoprotein Loses Its Anti-Inflammatory Properties During Acute Influenza A Infection
2001
Oxidized Lipids in Atherogenesis: Formation, Destruction and Action
1997
Decreased Protection by HDL From Poorly Controlled Type 2 Diabetic Subjects Against LDL Oxidation May Be Due to the Abnormal Composition of HDL
1999
Paraoxonase activity in two healthy populations with differing rates of coronary heart disease
2000
High-Density Lipoproteins Differentially Modulate Cytokine-Induced Expression of E-Selectin and Cyclooxygenase-2
1999
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Genetic Polymorphism of Paraoxonase and the Risk of Coronary Heart Disease
1997
Interactions between endothelial nitric oxide synthase and sex hormones in vascular protection in mice
2002 StandoutNobel
High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock
2001
Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions
1999
Atherosclerosis: Basic Mechanisms
1995 Standout
Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity
1999
Increased Cardiac Sympathetic Activity and Oxidative Stress in Habitual Electronic Cigarette Users
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Increased PAFAH and Oxidized Lipids Are Associated With Inflammation and Atherosclerosis in Hypercholesterolemic Pigs
2009
Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves
2009 StandoutNobel
HDL and the Inflammatory Response Induced by LDL-Derived Oxidized Phospholipids
2001
HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE −/− mice
2000
Serum Paraoxonase Activity, Concentration, and Phenotype Distribution in Diabetes Mellitus and Its Relationship to Serum Lipids and Lipoproteins
1995
Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity
1996
Inflammation and Atherosclerosis
2002 Standout
Paraoxonase and Atherosclerosis
2001 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Human Serum Paraoxonases (PON1) Q and R Selectively Decrease Lipid Peroxides in Human Coronary and Carotid Atherosclerotic Lesions
2000 Standout
Reduced Postprandial Serum Paraoxonase Activity After a Meal Rich in Used Cooking Fat
1999
Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor–Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E–Deficient Mice
2001
Small, Dense Lipoprotein Particles and Reduced Paraoxonase-1 in Patients with the Metabolic Syndrome
2005
Role of Group II Secretory Phospholipase A 2 in Atherosclerosis
1999
The Yin and Yang of Oxidation in the Development of the Fatty Streak
1996 Standout
Role of Group II Secretory Phospholipase A2in Atherosclerosis
1999
Paraoxonase PON1 Polymorphism Leu-Met54 Is Associated With Carotid Atherosclerosis
1998
Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression
2000
Paraoxonase-Gene Polymorphisms Associated with Coronary Heart Disease: Support for the Oxidative Damage Hypothesis?
1998
Increased Atherosclerosis in Mice Lacking Apolipoprotein A-I Attributable to Both Impaired Reverse Cholesterol Transport and Increased Inflammation
2005
Paraoxonase Active Site Required for Protection Against LDL Oxidation Involves Its Free Sulfhydryl Group and Is Different From That Required for Its Arylesterase/Paraoxonase Activities
1998
Determinants of Bioactivity of Oxidized Phospholipids
2000
Identification of the G994 → T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men
1998
Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity
2001
The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort
2004
Coronary Plaque Disruption
1995 Standout
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans
2002
Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism
1999
Direct Visualization of Lipid Deposition and Reverse Lipid Transport in a Perfused Artery
2000
Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study
2003
Increased Immunolocalization of Paraoxonase, Clusterin, and Apolipoprotein A-I in the Human Artery Wall With the Progression of Atherosclerosis
1997
Serum Paraoxonase and Platelet-Activating Factor Acetylhydrolase in Chronic Renal Failure
1998
Serum Paraoxonase After Myocardial Infarction
1999
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
1999
The Role of High-Density Lipoproteins in Oxidation and Inflammation
2001
Role of Monocytes in Atherogenesis
2003
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
2020
ESTROGENS AND ATHEROSCLEROSIS
1997
Decrease of serum paraoxonase activity in chronic renal failure.
1998
Functional Genomics of the Paraoxonase (PON1) Polymorphisms: Effects on Pesticide Sensitivity, Cardiovascular Disease, and Drug Metabolism
2003
Immune mechanisms in atherosclerosis.
1989
Immune Mechanisms in Atherosclerosis
2001
Antiinflammatory Properties of HDL
2004 Standout
Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties
2004
1999 George Lyman Duff Memorial Lecture
2000
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1
2000
Stimulation of Gsand Inhibition of GiProtein Functions by Minimally Oxidized LDL
1995
Role of Lipoprotein-Associated Phospholipase A 2 in Atherosclerosis
2005
Elevation of Plasma High-Density Lipoprotein Concentration Reduces Interleukin-1–Induced Expression of E-Selectin in an In Vivo Model of Acute Inflammation
2001
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Promoter Polymorphisms of Human Paraoxonase PON1 Gene and Serum Paraoxonase Activities and Concentrations
2000
Ambient Particulate Pollutants in the Ultrafine Range Promote Early Atherosclerosis and Systemic Oxidative Stress
2008
Works of A. D. Watson being referenced
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.
1995 Standout
Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
1995
Spironolactone use and renal toxicity: population based longitudinal analysis
2010